Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (CSE: INNO )

0.1700 -0.0100 (-5.56%)
Streaming Delayed Price Updated: 9:30 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,500
Open 0.1700
Bid (Size) 0.1650 (1,000)
Ask (Size) 0.1700 (69,500)
Prev. Close 0.1800
Today's Range 0.1700 - 0.1700
52wk Range 0.1500 - 0.3300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
Via Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-15.00%
-15.00%
1 Month
-10.53%
-10.53%
3 Month
-5.56%
-5.56%
6 Month
-19.05%
-19.05%
1 Year
-40.35%
-40.35%

More News

Read More
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Via Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Via Benzinga
Exposures Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Via Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Via Benzinga
Industry Update: Innocan Pharma Accelerates Commercialization in Europe Following Impressive Revenue Growth
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Innovative Delivery Systems Create Unique Opportunities in the Billion-Dollar Pain Market (CSE: INNO)
Via AB Newswire
Topics Cannabis
Exposures Cannabis
Innocan Pharma Provides an Operational Update
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
Via Newsfile
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Via Newsfile
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Via Newsfile
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence COVID-19 Supply Chain
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Via Newsfile
Topics Economy Supply Chain
Exposures COVID-19 Economy Supply Chain
Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.